Alzheimer; News from the web:

The companies developing aducanumab, Biogen and its partner Eisai, announced that they halted two late-stage trials of the experimental drug after an independent group’s analysis showed that the trials were unlikely to “meet their primary endpoint.”

The Cambridge, Massachusetts-based biotech giant joins a long list of companies in the last decade that have failed to find a treatment for Alzheimer’s.

Read all about it HERE